Gujarat Terce Laboratories MD, chairman, board of directors and AGM
BSE: 524314Pharmaceuticals & BiotechnologySmall Cap
Share price at the BSE close on 23 Oct 2026. Previous close ₹36.91.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹27 Cr3,856th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 7 Aug 2026
- 12.7
- P/E without one-offsPrice to earnings without one-off items. Market cap divided by core profit: the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, less one-off items (exceptional items and the result of businesses sold or closed). Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.45 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 10.5
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 30 May 2026
- 2.7
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 7 Aug 2026
- 25.8%
- ROE without one-offsReturn on equity without one-off items. Core profit, the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders less one-off items (exceptional items and the result of businesses sold or closed), as a percentage of the same net worth as the return on equity. Shown where the one-off items move that profit by more than a tenth. The last twelve months' profit includes −₹0.45 crore of one-off items, the largest of them in the quarter to Mar 2026.
- 31.4%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 7 Aug 2026
- 25.8%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 30 May 2026
- 0.13
- Volume, BSEVolume. Shares traded on the last trading day.
- 3,356
Gujarat Terce Laboratories board of directors
At the end of the quarter to Jun 2024, as the company filed it; changes since are in its announcements.Their trades in its shares
- ChairpersonNatwarbhai PrajapatiRelated to the promoter
- Company Secretary and Compliance OfficerRipal Sukhadiya
7 directors4 independent3 executive
- Natwarbhai Prajapati · ChairpersonExecutive · joined Mar 1985 · reappointed Aug 2022 · 1 listed board
- Amritbhai PrajapatiExecutive · joined Mar 2006 · reappointed Sep 2021 · 1 listed board
- CHHAYABEN ASHWINBHAI SHAHIndependent · joined Mar 2015 · reappointed Aug 2020 · 111 months as independent · 1 listed board · 1 as independent · 2 committee seats
- Viplav S. KhamarIndependent · joined Jun 2017 · reappointed Aug 2022 · 84 months as independent · 1 listed board · 1 as independent · 2 committee seats, 1 as chair
- Surendrakumar P. SharmaIndependent · joined Aug 2018 · reappointed Aug 2023 · 70 months as independent · 1 listed board · 1 as independent · 1 committee seat, 1 as chair
- Aalap PrajapatiExecutive · joined Apr 2018 · 1 listed board · 1 committee seat
- Navinchandra PatelIndependent · joined Feb 2020 · 52 months as independent · 1 listed board · 1 as independent
An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.
Committees and meetings
Who sits on each, and how often they met.Board meeting notices and outcomes
Board
- 20 Jun 20247 of 7 present4 independent · 21 days in between
- 29 May 20247 of 7 present4 independent · 60 days in between
- 29 Mar 20247 of 7 present4 independent
Audit Committee
Chair Surendrakumar P. Sharma
Viplav S. Khamar, CHHAYABEN ASHWINBHAI SHAH
- 29 May 20243 of 3 present3 independent · 113 days in between
- 5 Feb 20243 of 3 present3 independent
Nomination and remuneration committee
Chair Surendrakumar P. Sharma
Viplav S. Khamar, CHHAYABEN ASHWINBHAI SHAH
- 29 May 20243 of 3 present3 independent
- 5 Feb 20243 of 3 present3 independent
Stakeholders Relationship Committee
Chair Viplav S. Khamar
CHHAYABEN ASHWINBHAI SHAH, Aalap Prajapati
- 29 May 20243 of 3 present3 independent · 113 days in between
- 5 Feb 20243 of 3 present3 independent
Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.
Statutory auditor
Named in the results for the quarter to Mar 2026.
- Shah Doshi Patel & Associates LLPPeer-review certificate valid to Jul 2027
A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.
Gujarat Terce Laboratories AGM and shareholder votes
Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.Gujarat Terce Laboratories share news and announcements
Annual general meeting, 21 Aug 2026
13,775 shareholders on the register on 14 Aug 2026; present: 6 promoters and 32 others; votes counted by Ishan Shah / Ishan P. Shah.The company's voting result (opens in a new tab)
- Consideration and Adoption of the Audited Standalone Financial Statements of the Company for the financial year ended 31 March 2026 and the Reports of the Board of Directors and Auditors thereon.Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.55% · promoters 99.99% · institutions 0.00% · other public 7.54%
- Re-appointment of Mr. Natwarbhai Prajapati, as a Director liable to retire by rotationOrdinaryPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.55% · promoters 99.99% · institutions 0.00% · other public 7.54%
- Re-appointment of Mr. Aalap Prajapati as the Managing Director of the Company designated as "Managing Director & Chief Executive Officer" with effect from 28 October 2026 to 27 October 2029.SpecialPromoters have an interest in it100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.55% · promoters 99.99% · institutions 0.00% · other public 7.54%
- Resolution 4 : Ratification of Remuneration of M/s. K V M & Co., Cost Auditors — FY 2026-27Ordinary100.00% for0.00% against
Against: promoters 0.00% · institutions 0.00% · other public 0.00%
Turnout: all 44.55% · promoters 99.99% · institutions 0.00% · other public 7.54%
For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.
Compliance
- The board is made up as the listing rules require
- Yes
- The board has a regular chairperson
- Yes
- The company has a risk management committee
- No
- The chair is related to the managing director
- Yes
The company's own answers in its filing.
How money raised was used
Reported for the quarter to Dec 2025. The company's results filing for the quarter to Jun 2026 says no statement of how money raised was used applies to it. A preferential issue sells new shares to chosen investors rather than to the public. A warrant or partly paid issue plans the whole issue while the money comes in over time, so the amount set aside can be more than raised so far. A statement's amounts are left out where the raise it states is more than ten times everything the company owns, a figure typed at the wrong scale.
| Raised | Amount raised | For | Set aside | Spent | Spent elsewhere |
|---|---|---|---|---|---|
| Preferential IssuesDec 2025 | – | Business Operations | – | – | No |